Eli Lilly and Company (NYSE: LLY), a global healthcare conglomerate, has announced positive outcomes from a Phase II clinical trial of tirzepatide, a novel GIP/GLP-1 receptor agonist, in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. The study successfully achieved its primary endpoint, demonstrating resolution of MASH without exacerbation of fibrosis. Notably, a significant 73.3% of participants administered the maximum dosage reached the primary goal, contrasting with a mere 13.2% in the placebo cohort.
Furthermore, the trial data indicated that tirzepatide not only met its primary objectives but also showed promising improvements in secondary parameters such as body weight, liver injury, liver fat, and inflammation, with the latter not being a predefined trial objective. The safety profile of the drug was found to be consistent with previous reports, reinforcing its potential as a treatment for MASH.- Flcube.com
